Company news

AngioDynamics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

October 14, 2026

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

October 8, 2026

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

October 8, 2026

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

October 2, 2026

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

September 28, 2026

Press space to expand and collapse this section AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

July 14, 2026

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

July 14, 2026

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

June 30, 2026

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

June 17, 2026

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

May 28, 2026

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

May 13, 2026

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

April 1, 2026

AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference

March 31, 2026

AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

March 19, 2026

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

February 23, 2026

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

February 19, 2026

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

February 4, 2026

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

February 2, 2026

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

January 5, 2026

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

December 22, 2025

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 21, 2025

AngioDynamics to Participate in the UBS Global Healthcare Conference

October 26, 2025

AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List

October 12, 2025

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

October 1, 2025

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

September 17, 2025

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

July 27, 2025

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

July 22, 2025

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

July 14, 2025

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

July 6, 2025

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

June 23, 2025

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F18⁸⁵ System for Treatment of Acute Pulmonary Embolism

June 22, 2025

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

April 1, 2025

AngioDynamics to Host Virtual Cardiovascular Investor Event

March 30, 2025

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

March 18, 2025

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

March 9, 2025

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

January 29, 2025

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

January 12, 2025

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

January 7, 2025

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

January 5, 2025

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

January 5, 2025

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

December 18, 2024

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

December 8, 2024

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

October 22, 2024

AngioDynamics Announces American Medical Association’s CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

October 20, 2024

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

October 2, 2024

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

September 18, 2024

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

September 18, 2024

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

September 2, 2024

Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 89 decks. Every deck is listed under its year.